Dr. Crawford on Abiraterone Versus Enzalutamide in Prostate Cancer
E. David Crawford, MD, professor of Radiation Oncology, Department of Surgery, University of Colorado Denver, discusses factors in selecting abiraterone versus enzalutamide for the treatment of patients with castration-resistant prostate cancer.
E. David Crawford, MD, professor of Radiation Oncology, Department of Surgery, University of Colorado Denver, discusses factors in selecting treatment with abiraterone acetate (Zytiga) versus enzalutamide (Xtandi) for patients with castration-resistant prostate cancer (CRPC).
There are several factors that influence this decision, Crawford explains. For example, it depends whether patients have previously received anti-androgen therapies or agents such as ketoconazole. Crawford uses both enzalutamide and abiraterone in clinical practice, as well as studies the results of clinical trials investigating both therapies.
Further research is needed on whether using enzalutamide and abiraterone in combination demonstrates strong efficacy in these patients, Crawford adds.
<<<
